more "squawk on the street" in a minute. elmi d eln ly iryo. . ee ♪ >>> six minutes before we get to the opening bell this morning. you want to head to back to pharma. >> yes. and i think that what the president needs -- president-elect it would help if he would distinguish between companies putting price increases through for old drugs and innovation. because you don't want innovation to stop. witness ketruda for merck, breakthrough getting far bigger designation than we thought for cancer -- for breast cancer. and today delayed reaction. guggenheim, not the museum but the firm, piper and morgan stanley all say, yes, this is the one to buy. now, obviously the corollary is bristol-myers opdivo not doing well. but i like the fact what could happen here is if there's somehow this is something allergan's been talking about, brent saunders, somehow a distinction between older drugs and price competition and newer drugs and unfeddered prices because it's so expensive to bring a ketruda that -- i ain't going up the golden elevator that i've seen, but these analysts are saying, okay, use i